SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0969 9961 "

Sökning: L773:0969 9961

  • Resultat 61-70 av 197
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
61.
  •  
62.
  •  
63.
  • Guerreiro, R., et al. (författare)
  • Heritability and genetic variance of dementia with Lewy bodies
  • 2019
  • Ingår i: Neurobiology of Disease. - : Elsevier BV. - 0969-9961. ; 127, s. 492-501
  • Tidskriftsartikel (refereegranskat)abstract
    • Recent large-scale genetic studies have allowed for the first glimpse of the effects of common genetic variability in dementia with Lewy bodies (DLB), identifying risk variants with appreciable effect sizes. However, it is currently well established that a substantial portion of the genetic heritable component of complex traits is not captured by genome-wide significant SNPs. To overcome this issue, we have estimated the proportion of phenotypic variance explained by genetic variability (SNP heritability) in DLB using a method that is unbiased by allele frequency or linkage disequilibrium properties of the underlying variants. This shows that the heritability of DLB is nearly twice as high as previous estimates based on common variants only (31% vs 59.9%). We also determine the amount of phenotypic variance in DLB that can be explained by recent polygenic risk scores from either Parkinson's disease (PD) or Alzheimer's disease (AD), and show that, despite being highly significant, they explain a low amount of variance. Additionally, to identify pleiotropic events that might improve our understanding of the disease, we performed genetic correlation analyses of DLB with over 200 diseases and biomedically relevant traits. Our data shows that DLB has a positive correlation with education phenotypes, which is opposite to what occurs in AD. Overall, our data suggests that novel genetic risk factors for DLB should be identified by larger GWAS and these are likely to be independent from known AD and PD risk variants. © 2019 Elsevier Inc.
  •  
64.
  • Götze, Karl, et al. (författare)
  • Plasma neurofilament light chain in memory clinic practice: Evidence from a real-life study.
  • 2023
  • Ingår i: Neurobiology of disease. - : Elsevier BV. - 1095-953X .- 0969-9961. ; 176
  • Tidskriftsartikel (refereegranskat)abstract
    • To explore the accuracy of plasma neurofilament light chain (NfL) as a biomarker for diagnosis and staging of cognitive impairment, in a large cohort with of previously diagnosed patients in clinical practice.Retrospective, cross-sectional, monocentric study, from a tertiary memory clinic. Patients underwent cerebrospinal fluid core Alzheimer's disease (AD) biomarker evaluation using ELISA or Elecsys methods, and plasma NfL analysis using the single molecule array technology. The patients' biomarker data were examined for associations with: i/cognitive status ii/presence of neurodegenerative disease and iii/diagnostic groups. Associations between core CSF biomarkers and plasma NfL were determined.Participants (N=558, mean age=69.2±8.8, 56.5% women) were diagnosed with AD (n=274, considering dementia and MCI stages), frontotemporal dementia (FTD, n=55), Lewy body disease (LBD, n=40, considering MCI and dementia stages), other neurodegenerative diseases, n=57 (e.g Supranuclear Palsy, Corticobasal syndrome), non-neurodegenerative cognitive impairment (NND, n=79, e.g. vascular lesions, epilepsy or psychiatric disorders) or subjective cognitive impairment (SCI, n=53). Mean plasma NfL (log, pg/mL) levels were higher in neurodegenerative than non-neurodegenerative disorders (1.35±0.2 vs 1.16±0.23, p<0.001), higher in all diagnostic groups than in SCI (1.06±0.23) p<0.001), and associated with the stage of cognitive impairment (p<0.001). The addition of plasma NfL to a clinical model (age, MMSE and APOE ε4 carriership) marginally improved the discrimination of degenerative from non-degenerative disorders in ROC analysis (AUC clinical model: 0.81, 95% CI=[0.77;0.85] AUC clinical model + plasma NfL: AUC=0.83 95% CI=[0.78;0.87], delta Akaike information criterion=-11.7).Plasma NfL could help discrimination between degenerative and non-degenerative cognitive disorders, albeit not better than comprehensive clinical evaluation.
  •  
65.
  • Hagberg, Henrik, 1955, et al. (författare)
  • Perinatal brain damage: The term infant.
  • 2016
  • Ingår i: Neurobiology of disease. - : Elsevier BV. - 1095-953X .- 0969-9961. ; 92 (Pt A), s. 102-12
  • Forskningsöversikt (refereegranskat)
  •  
66.
  • Hansen, Christian, et al. (författare)
  • A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP.
  • 2013
  • Ingår i: Neurobiology of Disease. - : Elsevier BV. - 0969-9961. ; 56C:April,30, s. 145-155
  • Tidskriftsartikel (refereegranskat)abstract
    • Compelling evidence suggests that accumulation and aggregation of alpha-synuclein (α-syn) contribute to the pathogenesis of Parkinson's disease (PD). Here, we describe a novel Bacterial Artificial Chromosome (BAC) transgenic model, in which we have expressed wild-type human α-syn fused to green fluorescent protein (GFP), under control of the mouse α-syn promoter. We observed a widespread and high expression of α-syn-GFP in multiple brain regions, including the dopaminergic neurons of the substantia nigra pars compacta (SNpc) and the ventral tegmental area, the olfactory bulb as well as in neocortical neurons. With increasing age, transgenic mice exhibited reductions in amphetamine-induced locomotor activity in the open field, impaired rotarod performance and a reduced striatal dopamine release, as measured by amperometry. In addition, they progressively developed deficits in an odor discrimination test. Western blot analysis revealed that α-syn-GFP and phospho-α-syn levels increased in multiple brain regions, as the mice grew older. Further, we observed, by immunohistochemical staining for phospho-α-syn and in vivo by two-photon microscopy, the formation of α-syn aggregates as the mice aged. The latter illustrates that the model can be used to track α-syn aggregation in vivo. In summary, this novel BAC α-syn-GFP model mimics a unique set of aspects of PD progression combined with the possibility of tracking α-syn aggregation in neocortex of living mice. Therefore, this α-syn-GFP-mouse model can provide a powerful tool that will facilitate the study of α-syn biology and its involvement in PD pathogenesis.
  •  
67.
  •  
68.
  •  
69.
  • Helmfors, Linda, et al. (författare)
  • Protective properties of lysozyme on β-amyloid pathology : implications for Alzheimer disease
  • 2015
  • Ingår i: Neurobiology of Disease. - : Elsevier. - 0969-9961 .- 1095-953X. ; 83, s. 122-133
  • Tidskriftsartikel (refereegranskat)abstract
    • The hallmarks of Alzheimer disease are amyloid-β plaques and neurofibrillary tangles accompanied by signs of neuroinflammation. Lysozyme is a major player in the innate immune system and has recently been shown to prevent the aggregation of amyloid-β1-40 in vitro. In this study we found that patients with Alzheimer disease have increased lysozyme levels in the cerebrospinal fluid and lysozyme co-localized with amyloid-β in plaques. In Drosophila neuronal co-expression of lysozyme and amyloid-β1-42 reduced the formation of soluble and insoluble amyloid-β species, prolonged survival and improved the activity of amyloid-β1-42 transgenic flies. This suggests that lysozyme levels rise in Alzheimer disease as a compensatory response to amyloid-β increases and aggregation. In support of this, in vitro aggregation assays revealed that lysozyme associates with amyloid-β1-42 and alters its aggregation pathway to counteract the formation of toxic amyloid-β species. Overall, these studies establish a protective role for lysozyme against amyloid-β associated toxicities and identify increased lysozyme in patients with Alzheimer disease. Therefore, lysozyme has potential as a new biomarker as well as a therapeutic target for Alzheimer disease.
  •  
70.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 61-70 av 197
Typ av publikation
tidskriftsartikel (189)
forskningsöversikt (8)
Typ av innehåll
refereegranskat (195)
övrigt vetenskapligt/konstnärligt (2)
Författare/redaktör
Zetterberg, Henrik, ... (10)
Björklund, Anders (8)
Blennow, Kaj, 1958 (7)
Lundblad, Martin (7)
Kokaia, Zaal (6)
Ekdahl Clementson, C ... (5)
visa fler...
Zhu, J. (4)
Winblad, B (4)
Hagberg, Henrik, 195 ... (4)
Nordberg, A (3)
Diez, M (3)
Andersen, Peter M. (3)
Olson, L (3)
Möller, Christer (3)
Lannfelt, Lars (3)
Lindholm, Dan (2)
Bernardi, G. (2)
Link, H (2)
Almkvist, Ove (2)
Vandenberghe, R (2)
Londos, Elisabet (2)
Sandberg, Mats, 1953 (2)
Mix, E (2)
Mariotti, C. (2)
Hillert, J (2)
Olsson, T (2)
Ljunggren, HG (2)
Padovani, A (2)
Savic, I (2)
Wierup, Nils (2)
Lavebratt, C (2)
Tartaglia, MC (2)
Chen, ZG (2)
Spenger, C (2)
Brinkmalm, Gunnar (2)
Ingelsson, Martin (2)
Söderberg, Linda (2)
Andersson, M (2)
Smith, C (2)
Hardy, J (2)
Engel, J (2)
Andersson, My (2)
Mattsson, Bengt (2)
Adolfsson, R. (2)
Hokfelt, T (2)
Canlon, B (2)
Nath, Sangeeta (2)
Hansson, Oskar (2)
Blennow, Kaj (2)
Monni, Emanuela (2)
visa färre...
Lärosäte
Lunds universitet (90)
Karolinska Institutet (75)
Göteborgs universitet (19)
Uppsala universitet (14)
Umeå universitet (7)
Linköpings universitet (7)
visa fler...
Kungliga Tekniska Högskolan (5)
Stockholms universitet (3)
Örebro universitet (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (197)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (119)
Naturvetenskap (8)
Samhällsvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy